CU24093B1 - Derivados de isoquinolina vinculados al proceso de empalme celular - Google Patents

Derivados de isoquinolina vinculados al proceso de empalme celular

Info

Publication number
CU24093B1
CU24093B1 CU2011000230A CU20110230A CU24093B1 CU 24093 B1 CU24093 B1 CU 24093B1 CU 2011000230 A CU2011000230 A CU 2011000230A CU 20110230 A CU20110230 A CU 20110230A CU 24093 B1 CU24093 B1 CU 24093B1
Authority
CU
Cuba
Prior art keywords
group
empalme
cellular
hydroxyl
isoquinoline derivatives
Prior art date
Application number
CU2011000230A
Other languages
English (en)
Other versions
CU20110230A7 (es
Inventor
Jamal Tazi
Florence Mahuteau
Romain Najman
Didier Scherrer
Noëlie Campos
Aude Gardel
Original Assignee
Centre Nat Rech Scient
Inst Curie
Univ Montpellier 2
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Application filed by Centre Nat Rech Scient, Inst Curie, Univ Montpellier 2, Abivax filed Critical Centre Nat Rech Scient
Publication of CU20110230A7 publication Critical patent/CU20110230A7/es
Publication of CU24093B1 publication Critical patent/CU24093B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula (I) en donde: Fórmula (II) significa un grupo piridazina, pirimidina o pirazina, R independientemente representa un átomo de hidrógeno, átomo de halógeno o un grupo seleccionado de entre un grupo CN, un grupo hidroxilo, un grupo -COOR1, un grupo fluoroalquilo de C1-C3, un grupo fluoroalcoxi de C1-C4, un grupo fenoxi, y un grupo alquilo de C1-C3, el alquilo opcionalmente mono-sustituido por un grupo hidroxilo, n es 1, 2, o 3, n' es 1 o 2, R es un átomo de hidrógeno, un átomo de halógeno o un grupo seleccionado entre un grupo alquilo de C1-C3, un grupo hidroxilo, un grupo -COOR1, un grupo NO2, un grupo -NR1R2, un grupo morfolinilo o morfolino, un grupo N-metilpiperazinilo, un grupo fluoroalquilo de C1-C3, un grupo alcoxi de C1-C4, y un grupo CN, Z es N o C, Y es N o C, Z es N o C, W es N o C, T es N o C, U es N o C, para utilizarse como un agente para la prevención, inhibición o tratamiento de SIDA. Algunos de los compuestos son nuevos y también forman parte de la invención.
CU2011000230A 2009-06-12 2010-06-14 Derivados de isoquinolina vinculados al proceso de empalme celular CU24093B1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18655209P 2009-06-12 2009-06-12
US18654409P 2009-06-12 2009-06-12
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
PCT/IB2010/052651 WO2010143169A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating aids

Publications (2)

Publication Number Publication Date
CU20110230A7 CU20110230A7 (es) 2012-04-15
CU24093B1 true CU24093B1 (es) 2015-04-29

Family

ID=43309298

Family Applications (4)

Application Number Title Priority Date Filing Date
CUP2011000229A CU24124B1 (es) 2009-06-12 2010-06-14 N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer.
CU2011000228A CU24461B1 (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar envejecimiento prematuro y en particular progeria
CU2011000230A CU24093B1 (es) 2009-06-12 2010-06-14 Derivados de isoquinolina vinculados al proceso de empalme celular
CUP2015000024A CU24245B1 (es) 2009-06-12 2010-06-14 QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CUP2011000229A CU24124B1 (es) 2009-06-12 2010-06-14 N-fenil-naftalen-2-aminas sustituidas para el tratamiento del cáncer.
CU2011000228A CU24461B1 (es) 2009-06-12 2010-06-14 Compuestos útiles para tratar envejecimiento prematuro y en particular progeria

Family Applications After (1)

Application Number Title Priority Date Filing Date
CUP2015000024A CU24245B1 (es) 2009-06-12 2010-06-14 QUINOLIN-6 AMINA Y QUINOLINA-7-AMINA DERIVADOS DE LA FÓRMULA (Id) y (Ir), Y SALES DERIVADAS

Country Status (23)

Country Link
US (7) US20120277230A1 (es)
EP (6) EP2440547B1 (es)
JP (8) JP5826745B2 (es)
KR (14) KR101769616B1 (es)
CN (13) CN106905232B (es)
AU (3) AU2010258214B2 (es)
BR (5) BRPI1010772B8 (es)
CA (5) CA2965791C (es)
CU (4) CU24124B1 (es)
DK (4) DK2440547T3 (es)
ES (4) ES2736198T3 (es)
FI (3) FI3517534T3 (es)
HR (3) HRP20240582T1 (es)
HU (2) HUE045548T2 (es)
LT (1) LT2440547T (es)
MX (10) MX364279B (es)
PL (4) PL2440547T3 (es)
PT (4) PT2440547T (es)
RU (1) RU2567752C2 (es)
SI (1) SI2440547T1 (es)
TR (1) TR201910781T4 (es)
WO (3) WO2010143170A2 (es)
ZA (2) ZA201109032B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201910781T4 (tr) * 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
CN102656163B (zh) 2009-09-03 2016-01-13 拜奥埃内杰尼克斯公司 抑制pask的杂环化合物
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
US9073902B2 (en) 2011-01-05 2015-07-07 Bioenergenix, Llc Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
WO2012119046A2 (en) 2011-03-02 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) * 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
IN2014DN11205A (es) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2014065209A1 (ja) * 2012-10-23 2014-05-01 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9827237B2 (en) * 2013-07-05 2017-11-28 Abivax Compounds useful for treating diseases caused by retroviruses
WO2015005491A1 (ja) 2013-07-12 2015-01-15 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EP3105230B1 (en) 2014-02-14 2021-04-07 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
MX381238B (es) 2015-01-30 2025-03-12 Centre Nat Rech Scient Isoformas delta133p53beta y delta133p53gamma son biomarcadores de células madre cancerosas.
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
KR102828755B1 (ko) 2015-12-17 2025-07-03 바이오카인 테라퓨틱스 리미티드 케모카인 활성 및/또는 암세포 성장 억제용 저분자
WO2017103931A1 (en) 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
WO2017134098A1 (en) * 2016-02-03 2017-08-10 Janssen Pharmaceutica Nv Tau pet imaging ligands
US10464903B2 (en) * 2016-03-18 2019-11-05 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
EP3676252B1 (en) * 2017-08-29 2023-11-29 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
US12528810B2 (en) * 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
CA3090315C (en) 2019-05-15 2023-09-19 Biokine Therapeutics Ltd. 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
KR20220134569A (ko) * 2020-01-31 2022-10-05 아비박스 8-클로로-n-(4-(트리플루오로메톡시)페닐)퀴놀린-2-아민의 비정질 고체 분산체
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
BR112022018793A2 (pt) 2020-03-20 2022-11-29 Abivax Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
KR20230057341A (ko) 2020-07-02 2023-04-28 인사이트 코포레이션 Jak2 v617f 억제제로서 삼환계 우레아 화합물
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
KR20240014059A (ko) 2021-05-27 2024-01-31 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 퀴놀린아민 화합물, 이의 제조 방법 및 약제에서의 이의 용도
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023138657A1 (zh) * 2022-01-24 2023-07-27 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
PE20251706A1 (es) 2022-03-17 2025-07-02 Incyte Corp Compuestos de urea triciclica como inhibidores de v617f de jak2
WO2024109936A1 (zh) 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis
CN121532389A (zh) * 2023-08-30 2026-02-13 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (es) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) * 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) * 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
EP1165064B1 (en) 1999-04-05 2004-02-25 City of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
CN100378075C (zh) 2001-01-22 2008-04-02 记忆药物公司 用作磷酸二酯酶4抑制剂的苯胺衍生物
JP2005531574A (ja) 2002-05-22 2005-10-20 アムジエン・インコーポレーテツド 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (en) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
EP1601357A4 (en) * 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
MXPA06003607A (es) * 2003-10-16 2006-06-05 Chiron Corp Quinazolinas, quinoxalinas, quinolinas e isoquinolinas 2.6-disubstituidas como inhibidores de la cinasa raf para el tratamiento del cancer.
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CA2585490A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
US20090088513A1 (en) * 2005-06-29 2009-04-02 Adeka Corporation Resin additive composition and resin composition
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008008234A1 (en) * 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
AU2008206045A1 (en) * 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of MEK
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
WO2008115870A2 (en) * 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
TWI371445B (en) 2007-05-17 2012-09-01 Lg Chemical Ltd New anthracene derivatives and organic electronic device using the same
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2010536789A (ja) 2007-08-15 2010-12-02 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する３’置換化合物
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
JP2012514586A (ja) * 2009-01-05 2012-06-28 フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー．フアー． Ｉｌ−２１およびｉｌ−２１変異体に基づく抗体欠乏性疾患を治療するための手段および方法
BRPI1007222A2 (pt) * 2009-01-06 2016-02-23 Inserm Inst Nat De La Santé Et De La Rech Médicale agente de depleção de células b para tratamento de aterosclerose
US20120172617A1 (en) * 2009-01-06 2012-07-05 Werner Bonrath resveratrol intermediates dal
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
TR201910781T4 (tr) 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2903611A4 (en) 2012-10-04 2016-11-16 Oyagen Inc SMALL MOLECULES AS ANTI-HIV AGENTS FOR INTERRUPTING THE VIF SELF-ASSOCIATION AND METHOD FOR USE THEREOF
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Also Published As

Publication number Publication date
CN104844570A (zh) 2015-08-19
KR102016892B1 (ko) 2019-08-30
CN104945378A (zh) 2015-09-30
CN102596935B (zh) 2015-02-18
CN102625804A (zh) 2012-08-01
HK1212990A1 (zh) 2016-06-24
MX340095B (es) 2016-06-27
CN104945378B (zh) 2018-11-20
CN104945379A (zh) 2015-09-30
CU20150024A7 (es) 2015-09-29
HUE061262T2 (hu) 2023-05-28
JP7042245B2 (ja) 2022-03-25
EP2440547A2 (en) 2012-04-18
CN103948594A (zh) 2014-07-30
US20120283265A1 (en) 2012-11-08
US9908869B2 (en) 2018-03-06
EP3517534B1 (en) 2024-02-28
HK1200363A1 (en) 2015-08-07
AU2010258295A1 (en) 2012-01-19
CN106928205A (zh) 2017-07-07
BRPI1012892B1 (pt) 2020-10-27
CN106928194B (zh) 2019-11-12
BRPI1010768A2 (pt) 2016-11-01
CA2764027C (en) 2020-11-03
CU20110229A7 (es) 2012-06-21
EP3521283B1 (en) 2024-02-28
MX2011013119A (es) 2012-07-04
CN102574835A (zh) 2012-07-11
PL3517534T3 (pl) 2024-06-24
ES2736198T3 (es) 2019-12-26
FI2440546T3 (fi) 2023-03-30
CU24461B1 (es) 2020-01-03
US9145367B2 (en) 2015-09-29
WO2010143170A2 (en) 2010-12-16
PT2440545T (pt) 2019-07-19
CA2764027A1 (en) 2010-12-16
US20150307478A1 (en) 2015-10-29
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
LT2440547T (lt) 2023-03-10
JP2015187152A (ja) 2015-10-29
MX353776B (es) 2018-01-29
BR122019013687B1 (pt) 2020-04-14
KR101863021B1 (ko) 2018-05-30
JP2012529493A (ja) 2012-11-22
EP2440545B1 (en) 2019-04-24
JP2015187150A (ja) 2015-10-29
BRPI1012892B8 (pt) 2021-05-25
CA2965791C (en) 2020-06-09
CN104844510A (zh) 2015-08-19
KR101897221B1 (ko) 2018-09-10
PL2440545T3 (pl) 2019-11-29
JP5826745B2 (ja) 2015-12-02
CN106928205B (zh) 2019-09-24
KR20190018568A (ko) 2019-02-22
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
KR20180100737A (ko) 2018-09-11
CA2764024C (en) 2017-12-05
KR20190018570A (ko) 2019-02-22
KR20180100736A (ko) 2018-09-11
KR20190018569A (ko) 2019-02-22
BRPI1010772B8 (pt) 2021-05-25
CN102574835B (zh) 2014-04-16
HK1213246A1 (zh) 2016-06-30
HRP20230248T1 (hr) 2023-04-14
KR20180101727A (ko) 2018-09-13
PT3517534T (pt) 2024-05-17
FI3517534T3 (fi) 2024-05-16
AU2010258214A1 (en) 2012-01-19
KR20120049860A (ko) 2012-05-17
MX373120B (es) 2020-04-30
JP2015155453A (ja) 2015-08-27
MX364282B (es) 2019-04-22
EP2440546B1 (en) 2022-12-28
MX364280B (es) 2019-04-22
KR20190018567A (ko) 2019-02-22
KR20120054585A (ko) 2012-05-30
CN102625804B (zh) 2015-04-08
WO2010143169A3 (en) 2011-11-10
KR101982462B1 (ko) 2019-05-24
CN106905232B (zh) 2019-09-27
WO2010143168A3 (en) 2011-06-09
EP2440546A2 (en) 2012-04-18
WO2010143170A3 (en) 2011-08-11
HK1173447A1 (zh) 2013-05-16
CN113004249A (zh) 2021-06-22
CU20110230A7 (es) 2012-04-15
HK1173726A1 (zh) 2013-05-24
WO2010143168A2 (en) 2010-12-16
US9637475B2 (en) 2017-05-02
KR101982463B1 (ko) 2019-05-24
KR101769616B1 (ko) 2017-08-18
KR20190018571A (ko) 2019-02-22
AU2010258295B2 (en) 2015-09-03
DK2440545T3 (da) 2019-07-22
CN104844570B (zh) 2018-11-02
US20120329796A1 (en) 2012-12-27
US20140080831A1 (en) 2014-03-20
CN102596935A (zh) 2012-07-18
HRP20240582T1 (hr) 2024-07-19
ES2940885T3 (es) 2023-05-12
MX2011013122A (es) 2012-07-23
HK1173153A1 (en) 2013-05-10
CN103948594B (zh) 2016-10-26
DK2440546T3 (da) 2023-03-27
CA2764024A1 (en) 2010-12-16
PL2440547T3 (pl) 2023-09-11
JP5905385B2 (ja) 2016-04-20
JP2012529495A (ja) 2012-11-22
BRPI1010772B1 (pt) 2020-10-27
MX359575B (es) 2018-10-03
TR201910781T4 (tr) 2019-08-21
US20150299129A1 (en) 2015-10-22
KR20180100735A (ko) 2018-09-11
MX367601B (es) 2019-08-28
CA2965791A1 (en) 2010-12-16
EP3521283A1 (en) 2019-08-07
BRPI1012892A2 (pt) 2018-03-13
CN109776496B (zh) 2021-09-28
CN109776496A (zh) 2019-05-21
ZA201109031B (en) 2013-02-27
PT2440546T (pt) 2023-03-27
KR102016889B1 (ko) 2019-08-30
AU2010258294B2 (en) 2015-07-30
BRPI1010768C8 (pt) 2020-04-07
JP6158250B2 (ja) 2017-07-05
JP2020045342A (ja) 2020-03-26
CA2764026C (en) 2019-10-29
MX364279B (es) 2019-04-22
HK1213247A1 (zh) 2016-06-30
AU2010258214B2 (en) 2015-08-20
EP4198022A1 (en) 2023-06-21
ZA201109032B (en) 2013-02-27
US9108919B2 (en) 2015-08-18
HUE045548T2 (hu) 2019-12-30
US20120277230A1 (en) 2012-11-01
KR20170092720A (ko) 2017-08-11
CA3070823A1 (en) 2010-12-16
KR101789275B1 (ko) 2017-11-20
KR102016891B1 (ko) 2019-08-30
EP2440547B1 (en) 2022-11-30
MX364989B (es) 2019-05-17
ES2938532T3 (es) 2023-04-12
JP2012529494A (ja) 2012-11-22
KR20170124646A (ko) 2017-11-10
CN104844510B (zh) 2019-04-23
WO2010143169A2 (en) 2010-12-16
JP6041671B2 (ja) 2016-12-14
MX2011013120A (es) 2012-07-23
CA3070823C (en) 2021-09-21
AU2010258294A1 (en) 2012-01-19
BR122019013686B1 (pt) 2020-03-17
CA2764026A1 (en) 2010-12-16
HRP20230143T1 (hr) 2023-03-31
PL2440546T3 (pl) 2023-07-10
US20140288120A1 (en) 2014-09-25
EP2440545A2 (en) 2012-04-18
ES2985082T3 (es) 2024-11-04
PT2440547T (pt) 2023-02-17
RU2567752C2 (ru) 2015-11-10
JP6158251B2 (ja) 2017-07-05
CN104945379B (zh) 2018-11-30
KR101973348B1 (ko) 2019-04-26
DK3517534T3 (da) 2024-05-27
RU2011149571A (ru) 2013-07-20
CN106905232A (zh) 2017-06-30
JP2015187151A (ja) 2015-10-29
SI2440547T1 (sl) 2023-05-31
KR102016893B1 (ko) 2019-08-30
KR102016890B1 (ko) 2019-08-30
BRPI1010768B1 (pt) 2019-10-22
BRPI1010772A2 (pt) 2016-11-01
RU2011149572A (ru) 2013-07-20
EP3517534A1 (en) 2019-07-31
CU24245B1 (es) 2017-02-02
KR101982461B1 (ko) 2019-05-24
CN106928194A (zh) 2017-07-07
MX338823B (es) 2016-05-03
DK2440547T3 (da) 2023-02-20
KR20120051643A (ko) 2012-05-22
FI2440547T3 (fi) 2023-03-14
US10017498B2 (en) 2018-07-10
HK1212702A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
CU24093B1 (es) Derivados de isoquinolina vinculados al proceso de empalme celular
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
MX2014015501A (es) Carboxamidas heterociclicas fungicidas.
EA201170096A1 (ru) Замещенные производные пиримидона
MX2017010230A (es) Derivados de mono- y poliazanaftaleno sustituidos y su uso.
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
BR112013014943A8 (pt) Compostos da fórmula (i) e composição farmacêutica
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
EA201171062A1 (ru) Алкиламидные соединения и их применение
PE20200936A1 (es) Dihidrooxadiazinonas
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia
MX2019008390A (es) Compuestos utiles para tratar cancer.
CO6241116A2 (es) Pirimidil piperazinas utiles como ligandos del receptor d3/d2
ZA202106014B (en) Solid forms of condensed pyrazines as syk inhibitors
UY29023A1 (es) Procedimiento de preparacinn de derivados n- piperidino - 1, 5 - difenilpirazol - 3 - carboxamida.-
MX377854B (es) Derivado de 5-metil-6-fenil-4,5-dihidro-2h-piridazin-3-ona
MY161067A (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
MX2020014044A (es) Metodo para producir un derivado de (alfa)-azidoanilina o un derivado de (alfa), (alfa)'-diazida.
JP2012504601A5 (es)

Legal Events

Date Code Title Description
FG Grant of patent